Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848626 · ClinicalTrials.gov registry record
Study With Advanced Vaginal Tactile Imager
A clinical trial, sponsored by Artann Laboratories.
- Completed
- Registry status
- 22
- Enrollment target
NCT01848626: Completed study, sponsored by Artann Laboratories.
NCT01848626 is a clinical trial that has completed, run by Artann Laboratories. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01848626 has completed, sponsored by Artann Laboratories.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The objectives of this study are: 1. To collect data necessary for assessing the performance of advanced Vaginal Tactile Imager (VTI) and evaluating the probe ergonomic design, safety and patient tolerance; 2. To assess the clinical suitability of the interface software to facilitate the data collection process and to get in vivo examination data for validation of visualization and analysis routines; 3. To test the data collection technique and establish a reliable examination procedure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-03 |
What the finished NCT01848626 record still lists
NCT01848626 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01848626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01848626 about?
NCT01848626 is a clinical study titled "Study With Advanced Vaginal Tactile Imager". The objectives of this study are: 1. To collect data necessary for assessing the performance of advanced Vaginal Tactile Imager (VTI) and evaluating the probe ergonomic design, safety and patient tolerance; 2. To assess the clinical suitability of the interface software to facilitate the data colle...
What is the current status of trial NCT01848626?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2013-04. Estimated completion is 2014-03.
Who is sponsoring clinical trial NCT01848626?
This trial is sponsored by Artann Laboratories, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia